Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

ɪऎూ݋ᔼᖹ€ණྠٰ΅Ϟࠢʮ̡

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

€׵ʕശɛ͏΍ձ਷ൗ̅ϓٰͭٙ΅Ϟࠢʮ̡

(Stock Code/ٰ΅˾໮j02196)

NOTIFICATION LETTERc ஷٝڦՌ

28 April 2022

Dear Non-registered holder of H shares (Note),

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company")

Notice of Publication of Annual General Meeting Circular (the "Current Corporate Communications")

The English and Chinese versions of the Company's Current Corporate Communications are available on the websites of the Company (www.fosunpharma.com) and The Stock Exchange of Hong Kong Limited (www.hkexnews.hk).

If you want to receive a printed version of the Current Corporate Communications, please complete and sign the Request Form on the reverse side and return it to H share registrar of the Company, Tricor Investor Services Limited (the "H Share Registrar") by using the mailing label at the bottom of the Request Form (no stamp is required if posted in Hong Kong; otherwise, please affix an appropriate stamp). The address of the H Share Registrar is Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong. You may also send an email with a scanned copy of the completed and signed Request Form tois-ecom@hk.tricorglobal.com. The Request Form may also be downloaded from the websites of the Company (www.fosunpharma.com) and The Stock Exchange of Hong Kong Limited (www.hkexnews.hk).

Should you have any queries relating to this letter, please contact the H Share Registrar at (852) 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m. from Monday to Friday, excluding Hong Kong public holidays.

Yours faithfully

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd*

Wu Yifang

Chairman

Note:This letter is addressed to non-registered holders of H shares ("Non-registered holder of H shares" means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited to receive Corporate Communications). If you have sold or transferred your shares in the Company, please disregard this letter and the Request Form on the reverse side.

*For identification purposes only.

΢Зڢ೮া H ٰٰ؇€ڝൗj

ɪऎూ݋ᔼᖹ€ණྠٰ΅Ϟࠢʮ̡€˜͉ʮ̡™ ೯бٰ؇඄ϋɽึஷՌ€˜݊ϣʮ̡ஷৃ™

͉ʮ̡ٙ݊ϣʮ̡ஷৃʘߵ˖ʿʕ˖و͉ʊɪ༱׵͉ʮ̡ၣ१ (www.fosunpharma.com) ʿ࠰ಥᑌΥʹ׸הϞࠢʮ̡ၣ१

(www.hkexnews.hk)f

ࡊ ტɨ૧ϗ՟݊ϣʮ̡ஷৃʘΙՏ͉dሗ෬Ѽʿᖦ໇ί͉Ռߠࠦٙ͡ሗڌࣸdԨԴ͜͡ሗڌֵࣸ௅ʘඉ੔ᅺᜀ੔Ϋ͉ʮ̡ʘ H ٰٰ΅ཀ˒೮াஈՙԳᗇՎ೮াϞࠢʮ̡€˜ H ٰٰ΅ཀ˒೮াஈ ™€νί࠰ಥҳ੔dˡ඲൨ɪඉୃiщۆdሗ൨ɪቇ຅ٙඉୃf H ٰٰ΅ཀ˒೮াஈήѧމ࠰ಥᝄ˺ެΧɽ༸؇ 183 ໮Υձʕː 54 ᅽf ტɨ͵̙Ҫʊ෬Ѽʿᖦ໇ʘ͡ሗڌࣸٙધ౜ਓ͉ཥඉЇis-ecom@hk.tricorglobal.com f͡ሗڌࣸ͵̙׵͉ʮ̡ၣ१ (www.fosunpharma.com) ʿ࠰ಥᑌΥʹ׸הϞࠢʮ̡ၣ१ (www.hkexnews.hk)

ɨ༱f

ࡊ ტɨ࿁͉Ռʫ࢙Ϟ΂Оဲਪdሗ׵፬ʮࣛගʫdу݋ಂɓЇ݋ಂʞ€࠰ಥʮ଺৿ಂৰ̮ɪʹ 9 ͍ࣛЇɨʹ 6 ͍ࣛdߧཥ H ٰٰ΅ ཀ˒೮াஈʘཥ༑ (852)2980 1333 ݟ༔f

Ϥߧ ו໨ԫึն ɪऎూ݋ᔼᖹ€ණྠٰ΅Ϟࠢʮ̡ ю˸ٹ ໨ԫڗ ᔫ઼ 2022 ϋ 4 ˜ 28˚

ڝൗj ϤՌ΁ɗΣڢ೮া H ٰٰ؇€˜ڢ೮া H ٰٰ؇™ܸՉٰ΅π׳׵ʕ̯ഐၑʿʹϗӻ୕ٙɛɻאʮ̡dீཀ࠰ಥʕ̯ഐၑϞࠢʮ̡ʔࣛΣ͉ʮ̡ ೯̈ஷٝdڌͪ૧ϗՑ͉ʮ̡ʘʮ̡ஷৃ೯̈fࡊ ტɨʊ຾̈ਯאᔷᜫהܵϞʘ͉ʮٰ̡΅dۆˡ඲ଣึ͉Ռʿߠࠦٙ͡ሗڌࣸf

*

සԶᗆйʘ͜

Shareholder's information (Full name and address)

ٰ؇༟ࣘ€ΌΤʿήѧ

REQUEST FORMc ͡ሗڌࣸ

To:

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company") ߧj ɪऎూ݋ᔼᖹ€ණྠٰ΅Ϟࠢʮ̡€˜͉ʮ̡™

(Stock Code: 02196)

c/o Tricor Investor Services Limited

Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong

€ٰ΅˾໮j 02196 ຾ՙԳᗇՎ೮াϞࠢʮ̡ ࠰ಥެΧɽ༸؇ 183 ໮Υձʕː 54

I/We would like to receive the Current Corporate Communications and all future corporate communications# of the Company ("Corporate Communications") in the manner as indicated below:

͉ɛŊҢࡁҎૐ˸ɨΐ˙όϗ՟൮ʮ̡ʘ݊ϣʿהϞ˚ܝʮ̡ஷৃ€˜ʮ̡ஷৃ™j

(Please mark a "" in ONLY ONE of the following boxes)

€ሗ ίɨΐՉʕɓࡈ٤ࣸʫྌɪ˜™໮

#

to receive the printed English version of the current and all future Corporate Communications ONLY; OR ϗ՟݊ϣʿהϞ˚ܝʮ̡ஷৃʘߵ˖ΙՏ͉ iא

to receive the printed Chinese version of the current and all future Corporate Communications ONLY; OR ϗ՟݊ϣʿהϞ˚ܝʮ̡ஷৃʘʕ˖ΙՏ͉ iא

to receive both the printed English and Chinese versions of the current and all future Corporate Communications.

Νࣛϗ՟݊ϣʿהϞ˚ܝʮ̡ஷৃʘߵ˖ʿʕ˖ΙՏ͉f

Non-registered holder of H shares' s full name

ڢ೮া H ٰٰ؇ΌΤj

Address ήѧj

(Please use BLOCK LETTERS ሗฺ͍͜෬ᄳ

Contact telephone number ᑌഖཥ༑໮ᇁj

Notes ڝൗj

1. Please complete all your details clearly.

ሗ ტɨ૶ู෬ѼהϞ༟ࣘf

Signature ᖦΤjDate ˚ಂj

2.

This letter is addressed to non-registered holders of H shares ("non-registered holder of H shares" means such person or company whose shares are held in The Central

Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited to receive

Corporate Communications).

ϤՌ΁ɗΣڢ೮া H ٰٰ؇€˜ڢ೮া H ٰٰ؇™ܸՉٰ΅π׳׵ʕ̯ഐၑʿʹϗӻ୕ٙɛɻאʮ̡dீཀ࠰ಥʕ̯ഐၑϞࠢʮ̡ʔࣛΣ͉ʮ̡೯

̈ஷٝdҎૐϗՑʮ̡ஷৃ೯̈f

3.

Any form with more than one box marked "", with no box marked "", with no signature or otherwise incorrectly completed will be void.

νί͉ڌࣸЪ̈൴ཀɓධ፯኿eא͊ϞЪ̈፯኿eא͊Ϟᖦ໇eאίՉ˼˙ࠦ෬ᄳʔ͍ᆽdۆ͉ڌࣸਗ਼ึЪᄻf

4.

The above instruction will apply to the current and all future Corporate Communications to be sent to you until you notify the Company c/o Tricor Investor Services

Limited to the contrary or unless you have at anytime ceased to hold shares of the Company.

ɪࠑܸͪቇ͜׵೯৔ʚ ტɨʘ݊ϣʿהϞ˚ܝʮ̡ஷৃdٜЇ ტɨ຾ՙԳᗇՎ೮াϞࠢʮ̡ஷ͉ٝʮ̡̤̮ʘτરא΂Оࣛࡉ৾˟ܵϞ͉

ʮٰ̡ٙ΅f

5.

For the avoidance of doubt, the Company will not accept any special instructions written on this Request Form.

މе͛ဲਪd΂Оί͉͡ሗڌࣸɪٙᕘ̮˓ᄳܸͪd͉ʮ̡ਗ਼ʔʚஈଣf

#

Corporate Communications refer to any document issued or to be issued by the Company for the information or action of holders of any of the Company's securities,

including but not limited to: (a) annual report; (b) interim report; (c) notice of meeting; (d) listing document; (e) circular; and (f) proxy form.

#

ʮ̡ஷৃܸ͉͟ʮ̡೯̈אਗ਼ʚ೯̈˸Զ͉ʮ̡΂ОᗇՎٙܵϞɛਞ๫אમ՟Бਗٙ΂О˖΁dՉʕܼ̍Шʔࠢ׵j (a) ϋ జi (b) ʕಂజѓi (c)

ᙄஷѓi (d) ɪ̹˖΁i (e) ஷ Ռiʿ (f) ˾ڌ։΂ڌࣸf

*

For identification purposes only

*

සԶᗆйʘ͜

MAILING LABEL ඉ੔ᅺᜀ

ტɨ੔ΫϤ͡ሗڌࣸࣛdሗਗ਼ඉ੔ᅺᜀ਒൨׵ڦ܆ɪf νί࠰ಥҳ੔dˡ඲൨ɪඉୃf

Please cut the mailing label and stick it on an envelope to return this Request Form to us.

No postage stamp is necessary if posted in Hong Kong.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 28 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 April 2022 10:45:46 UTC.